Biology and genomics
| Abstracts Book Number | Category | Title | First author |
| 469 | Biology and genomics | CUEDC2 Promotes Tumor Proliferation in Diffuse Large B-Cell Lymphoma via Ubiquitination of PP2AB55 | Liang Wang |
| 470 | Biology and genomics | Effect of BCOR frameshift mutations on its expression in lymphoma cell lines | Weronika Sura |
| 471 | Biology and genomics | Longitudinal scRNA-seq Case Study Identifies Three Stable and Distinct B-Cell Subtypes In Serial Samples of a Diffuse B-Cell Lymphoma from a Single Dog | Grace Walker |
| 472 | Biology and genomics | The heterogeneity and related prognostic factors of primary central nervous system diffuse large B-cell lymphoma based on single-cell sequencing technology | Tian chang |
| 473 | Biology and genomics | LncRNA-BCYRN1 drives the polarization of tumor-associated macrophages towards the M2 phenotype in NK/T cell lymphoma | Liang Wang |
| 474 | Biology and genomics | CD73 modulates immune escape via tryptophan metabolic reprogramming in diffuse large B-cell lymphoma | Yingfang Feng |
| 475 | Biology and genomics | Single-cell RNA Sequencing analysis of CAR-T cell infusion products indicates 'viral mimicry' as potential resistance mechanism | Liang Wang |
| 476 | Biology and genomics | Spatial Transcriptomics Identifies Prognostic LYZ+ Fibroblasts and Their Colocalization with FN1+ Macrophages in Diffuse Large B-Cell Lymphoma | Liyuan Dai |
| 477 | Biology and genomics | Longitudinal multi-omics investigation in Ibrutinib-Bortezomib-R-CHOP-treated DLBCL patients | Sophy Denker |
| 478 | Biology and genomics | Single-Cell RNA Sequencing Uncovers AP-1 Transcriptional Upregulation in Canine Diffuse Large B-Cell Lymphoma | Aaron Lyman Sarver |
| 479 | Biology and genomics | DLBCL-associated PIM1 mutation drives ANXA2 relocation on the membrane and promotes lymphomagenesis | Yaxiao Lu |
| 480 | Biology and genomics | Latent Membrane Proteins 1 and 2 promote EBV-mediated B-cell transformation by activation of the protease MALT1 | Mélanie Juilland-Favre |
| 481 | Biology and genomics | Adaptive resistance in lymphoproliferative disorders: potential roles of SNHG32, a novel non-coding tumour suppressor | Indrani Karpha |
| 482 | Biology and genomics | Bystander activation drives CD8+ T cells response in Lymphoma-associated Hemophagocytic Lymphohistiocytosis | Jing Quan Lim |
| 483 | Biology and genomics | Single-cell and spatial transcriptomic profiling identifies M1 macrophage-mediated tumor suppression in monomorphic epitheliotropic intestinal T-cell lymphoma | Ji-nuo Wang |
| 484 | Biology and genomics | Single-Cell Analysis of Circulating Immune Heterogeneity in diffuse large B-cell lymphoma Highlights distinct Immune cell signatures in Immunotherapy | Sicong Zhang |
| 485 | Biology and genomics | Exosomal BCYRN1 in NK/T - cell Lymphoma: Unveiling Its Role in Macrophage Polarization and Tumor Progression | Liang Wang |
| 486 | Biology and genomics | TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering NK cells via MYC-CD47/PD-L1 axis | YUE ZHU |
| 487 | Biology and genomics | MicroRNAs target tumor suppressor GRK2 in MALT1-Dependent diffuse large B-cell lymphoma | Jing Cheng |
| 488 | Biology and genomics | Multi-dimensional Transcriptomic Profiling and Tumor Microenvironment Subtyping of Multi-site Mucosa-Associated Lymphoid Tissue Lymphomas | Yijun Wu |
| 489 | Biology and genomics | Targeting IL-1β/IL-1R/IL-1R signaling in IRF2BP2-mutant diffuse large B cell lymphoma | Areya Tabatabai |
| 490 | Biology and genomics | Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses | Cong Sun |
| 491 | Biology and genomics | Spatial transcriptomics of follicular (FL) and marginal zone lymphomas (MZL) identifies domains of CD8+ T cell recruitment and exclusion | Ari Pelcovits |
| 492 | Biology and genomics | Pseudo-Double-Hit Large B-Cell Lymphomas (LBCL): Are MYC and BCL6 Married? | Nicolas De Lucas Torres |
| 493 | Biology and genomics | Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass | Shu Zhao |
| 494 | Biology and genomics | Immunoprofiling of the Tumor Microenvironment in DLBCL Using Multiplexed Immunofluorescence and QuPath analysis | Jamileh Hashemi |
| 495 | Biology and genomics | Characterizing Tumor Microenvironment Heterogeneity in EBV+nTNKL vs ENKTCL Using Spatial Transcriptomics and mIF | Siyu Qian |
| 496 | Biology and genomics | Patients with lymphoma in high risk of treatment-related death can be identified by CHIP and mosaic chromosomal alterations | Mathias Aerendahl Heldbo |
| 497 | Biology and genomics | Shift towards more naïve phenotype of the T cell compartment in patients with aggressive B cell non-Hodgkin lymphoma undergoing high dose methotrexate therapy | Vanessa Ridder |
| 498 | Biology and genomics | Mendelian Randomization reveals the causative role of genetically predicted viral Infection in pan-lymphoma risk | Tao You |
| 499 | Biology and genomics | Pesticide exposure in farmers increases the frequency of blood cells carrying the t(14;18) BCL2-IGH. | Anne-Claire GAC |
| 500 | Biology and genomics | A comparative analysis of the impact of novel BTK inhibitors and venetoclax on dendritic cell and T cell function | Gina Gerhorst |
| 501 | Biology and genomics | Novel Role of Chidamide in TAM Reprogramming and Immunotherapy Enhancement through RNA Splicing | Caiqin Wang |
Clinico-pathologic correlations
| Abstracts Book Number | Category | Title | First author |
| 502 | Clinico-pathologic correlations | Biomarkers of Immune Checkpoint Inhibitors Response in Patients with Lymphoma: Results from Real-World Cohorts | Yuxuan Che |
| 503 | Clinico-pathologic correlations | Evaluating the Prognostic Significance of C-Reactive Protein to Albumin Ratio in Patients with Non-Hodgkin Lymphoma | Rukesh Yadav |
| 504 | Clinico-pathologic correlations | Impact of the Neutrophil/Lymphocyte Ratio (NLR) on outcomes following bispecific antibody (BsAb) therapy in relapsed/refractory (R/R) lymphoma patients | Allison M. Bock |
| 505 | Clinico-pathologic correlations | Emerging Evidence of Microbiota Composition Linked to Adverse Events During Immunotherapy in Dogs with Lymphoma | Amy Treeful |
| 506 | Clinico-pathologic correlations | Evaluation of Ultrasensitive in situ Hybridization (ISH) mRNA Technology Versus Immunohistochemistry (IHC) for Determining Light Chain Restriction in B-cell Neoplasms | Bowdoin Su |
Imaging and radiomics
| Abstracts Book Number | Category | Title | First author |
| 507 | Imaging and radiomics | [18F]FDG PET/MRI FOR ASSESSING TREATMENT RESPONSE OF CNS LYMPHOMA: A PROSPECTIVE CASE SERIES | Patricia López-Pereira |
| 508 | Imaging and radiomics | Bayesian penalized likelihood reconstruction algorithm results in similar prognostic markers on FDG PET/CT in DLBCL | Hian Liang Huang |
| 509 | Imaging and radiomics | [18F]-FDG-PET/CT-based Prognostic criteria in Follicular Lymphoma | Yuliya Sauchuk |
| 510 | Imaging and radiomics | The Antibody-Dependent Cellular Cytotoxicity and Metabolic Tumor Volume Balance: A Novel Predictive Marker for Tumor Recurrence in Diffuse Large B-Cell Lymphoma | Sofia Rincon-Lopez |
| 511 | Imaging and radiomics | Accuracy of percutaneous ultrasound-guided needle biopsy of abdominal lymph-nodes for the diagnosis of malignant disease | Camilla Mazzoni |
| 512 | Imaging and radiomics | Prognostic Value of Baseline Metabolic Biomarkers Assessed by F18-FDG PET/CT in Diffuse Large B-Cell Lymphoma | Lintao Bi |
| 513 | Imaging and radiomics | Prognostic predictive value of baseline 18F-FDG PET/CT metabolic parameters in Hodgkin's lymphoma | Jingyan Xu |
| 514 | Imaging and radiomics | Can Baseline 18F-FDG PET/CT Predict the Prognosis of Primary CNS Lymphoma? | Huiying Zhu |
| 515 | Imaging and radiomics | PREDICTIVE VALUE OF INTERIM AND END OF TREATMENT PET/CT IN FRONT-LINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA | Eva Domingo Domenech |
| 516 | Imaging and radiomics | Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study | Jiesong Wang |
| 517 | Imaging and radiomics | 18F-FDG PET radiomics score construction by automatic machine learning for treatment response prediction in elderly patients with DLBCL: a multicenter study | Jingyan Xu |
| 518 | Imaging and radiomics | Computed Tomography Body Composition in a Prospective Cohort Study of Older Adults with Aggressive Lymphomas: Association with Survival, Toxicity, and Healthcare Use | Patrick Connor Johnson |
| 519 | Imaging and radiomics | Personalized Baseline and Residual TMTV Influence Treatment Response and Outcomes in Relapsed/Refractory Lymphomas: Results from the GATA Study | Yassine Al Tabaa |
| 520 | Imaging and radiomics | The role of Laboratory Prognostic Index and Metabolic Tumor Volume in predicting Diffuse Large B-Cell Lymphoma patients potentially curable with R-CHOP | Carlos Grande García |
| 521 | Imaging and radiomics | HAIPI: an AI-based Model Improving the International Prognostic Index (IPI) for DLBCL | Shenmiao YANG |
| 522 | Imaging and radiomics | Clinical approach and outcome of Diffuse Large B Cell Lymphoma with persistent PET positivity after frontline treatment: subgroup analysis of the STRIDER Study | Mattia Novo |
| 523 | Imaging and radiomics | Correlation of baseline PET/CT imaging and molecular features with clinical outcomes in a population-based MCL study | Amanda Isabel Perez-Valencia |
Liquid Biopsy
| Abstracts Book Number | Category | Title | First author |
| 524 | Liquid Biopsy | Profiling of Circulating Epigenetic Marks in Lymphoma Patients | Karolina Sienkiewicz |
| 525 | Liquid Biopsy | Integrated multi-omics of plasma proteome and transcriptome with single-cell analyses identify potential therapeutic targets for diffuse large B-cell lymphoma | Yijun Wu |
| 526 | Liquid Biopsy | Exploration of Low-Pass Whole-Genome Sequencing Technology Based on ctDNA for Detection of Minimal Residual Disease in Diffuse Large B Cell Lymphoma | Xudong Zhang |
| 527 | Liquid Biopsy | High-throughput T cell receptor sequencing to detect measurable residual disease in systemic T cell lymphoma treated with brentuximab vedotin: a prospective trial | Michael P. Randall |
| 528 | Liquid Biopsy | Detection of recurrent genomic alterations and minimal residual disease with cell-free DNA and bone marrow in Waldenström’s Macroglobulinemia | Signy Chow |
| 529 | Liquid Biopsy | Diagnostic and prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by ddPCR in patients with AITL | Huayuan Zhu |
| 530 | Liquid Biopsy | Predictive Value of ctDNA and MRD Dynamics in Diffuse Large B-Cell Lymphoma: AProspective Cohort Study | Wei Liu |
| 531 | Liquid Biopsy | Adjustment of chemotherapy duration according to peripheral blood orbone marrow minimal residual disease status in patients with follicular lymphoma | Uri Abadi |
| 532 | Liquid Biopsy | Unraveling MRD Dynamics to Enhance Outcome Prediction in Mantle Cell Lymphoma – Insights from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial | Francesca Cordero |
Chronic lymphocytic leukemia
| Abstracts Book Number | Category | Title | First author |
| 533 | Chronic lymphocytic leukemia | Efficacy and Safety of Minimal Residual Disease-Guided Immunochemotherapy plus Fixed-duration BTKi in Young, Treatment-Naïve Chronic Lymphocytic Leukemia Patients | Xixi Xiang |
| 534 | Chronic lymphocytic leukemia | EFFICACY OF BTK INHIBITOR-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) -- A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS | Yutong Wang |
| 535 | Chronic lymphocytic leukemia | A Multi-Country Analysis of the Cost of Managing Adverse Events in Chronic Lymphocytic Leukemia | Jackie Thomson |
| 536 | Chronic lymphocytic leukemia | Orelabrutinib-based regimens in chronic lymphocytic leukemia: a real-world study | Zi Wang |
| 537 | Chronic lymphocytic leukemia | Clinical Characteristics of hepatitis B virus reactivation in chronic lymphocytic leukemia patients treated with ibrutinib: A retrospective multicentric study | Joon Young Hur |
| 538 | Chronic lymphocytic leukemia | IGVH Mutational Status as a Prognostic Factor Affecting Relapse-Free Survival and Treatment-Free Interval in CLL Patients: Single-Center Experience with 110 Cases | Taner Tan |
| 539 | Chronic lymphocytic leukemia | The Landscape of Chronic Lymphocytic Leukemia in Egypt: Results from the Regional CREEK Study Subgroup Analysis | Gamal Fathy |
| 540 | Chronic lymphocytic leukemia | SAFETY OF BTK INHIBITOR-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) -- A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS | Yutong Wang |
| 541 | Chronic lymphocytic leukemia | TARGETED NANOPORE SEQUENCING FOR TP53 MUTATION DETECTION IN CLL PATIENTS IN A RESOURCE-LIMITED SETTING | Aidos Akhmetali |
| 542 | Chronic lymphocytic leukemia | Real-World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Lukemia/Small Lymphocytic Lymphoma | Huayuan Zhu |
| 543 | Chronic lymphocytic leukemia | Obinutuzumab-Induced ADCC as a Predictor of Minimal Residual Disease in Chronic Lymphocytic Leukemia: A Preliminary Study | Ricardo García-Muñoz |
| 544 | Chronic lymphocytic leukemia | Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia | Talha Munir |
| 545 | Chronic lymphocytic leukemia | ADIPONECTIN’S SERUM LEVEL CORRELATION WITH KNOWN PROGNOSTIC FACTORS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE STUDY IN TREATMENT NAÏVE CLL PATIENTS | Claudia Giordano |
| 546 | Chronic lymphocytic leukemia | Patient reported outcomes and predictors of inhibitor use in chronic lymphocytic leukemia- an analysis of the Lymphoma Coalition’s 2024 Global Patient Survey | Natacha Bolaños |
| 547 | Chronic lymphocytic leukemia | A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL) | Tingyu Wang |
| 548 | Chronic lymphocytic leukemia | Evolving Treatment Patterns and Biomarker Utilization for Chronic Lymphocytic Leukemia in Latin America: A Multinational Real-World Study | Ana Carolina Oliver |
| 549 | Chronic lymphocytic leukemia | Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making | Sikander Ailawadhi |
| 550 | Chronic lymphocytic leukemia | Phase II trial of Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: the cwcll-001 trial | Huayuan Zhu |
| 551 | Chronic lymphocytic leukemia | A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL) | Mazyar Shadman |
| 552 | Chronic lymphocytic leukemia | Bruton's Tyronsine Kinase Inhibitors Versus Venetoclax in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Retrospective Real-World Analysis. | Avery Zickar |
| 553 | Chronic lymphocytic leukemia | Digital technology and natural language processing in action: exploring the Belgian chronic lymphocytic leukemia (CLL) patient population with the BE-CLLEAR study | Matthias Vanderkerken |
| 554 | Chronic lymphocytic leukemia | Risk of Hypertension in Patients Diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Bruton Tyrosine Kinase Inhibitors: A Real-World Study | Nicole Lamanna |
| 555 | Chronic lymphocytic leukemia | Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia | Nicole Lamanna |
| 556 | Chronic lymphocytic leukemia | Impact of tumor burden and prior venetoclax treatment on mosunetuzumab-mediated tumor control in relapsed/refractory CLL | Hyun Yong Jin |
| 557 | Chronic lymphocytic leukemia | Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia | Joanna M. Rhodes |
| 558 | Chronic lymphocytic leukemia | Preferences for Treatment in First-Line Chronic Lymphocytic Leukemia (CLL): A Multi-Criteria Decision Analysis (MCDA) in Italy | Antonio Cuneo |
Follicular Lymphoma
| Abstracts Book Number | Category | Title | First author |
| 559 | Follicular Lymphoma | Patients with lymphoproliferative disease exhibit altered haemostasis. Thrombin generation provides mechanistic insights- a potential biomarker of thrombosis | Aimee Tran |
| 560 | Follicular Lymphoma | An Advanced Deep Learning Strategy for Accurate Pathological Subtyping of Lymphoma | ZHITAO YING |
| 561 | Follicular Lymphoma | Prognostic Impact of the Mutational Profile in Follicular Lymphoma Treated with First-Line Immunochemotherapy | Javier Marco Ayala |
| 562 | Follicular Lymphoma | High Incidence of Thrombocytopenia During Obinutuzumab-Based Chemotherapy in Previously Untreated Follicular Lymphoma: A Retrospective Real-World Analysis from China | jingxin zhou |
| 563 | Follicular Lymphoma | Patient preferences for relapsed/refractory follicular lymphoma (R/R FL) in the novel treatment era: interim survey results | Krish Patel |
| 564 | Follicular Lymphoma | Adherence to the 2-year maintenance therapy protocol with anti-CD20 monoclonal antibodies positively impacts clinical outcomes of follicular lymphoma patients | Shimrit Ringelstein-Harlev |
| 565 | Follicular Lymphoma | CD19-Targeted CAR-T Therapy in Transformed Follicular Lymphoma: Efficacy, Safety, and Molecular Insights | Rui Liu |
| 566 | Follicular Lymphoma | Real-world outcomes of mosunetuzumab use from the CUBIC consortium | Andrew Jallouk |
| 567 | Follicular Lymphoma | REAL-WORLD EVALUATION OF TREATMENTS AND OUTCOMES OF FOLLICULAR LYMPHOMA IN BELGIUM | Willem Daneels |
| 568 | Follicular Lymphoma | REAL-WORLD DATA ANALYSIS WITH INFORMATICS FOR INTEGRATING BIOLOGY AND THE BEDSIDE (I2B2): A RELIABLE TOOL FOR EVIDENCE GENERATION IN FOLLICULAR LYMPHOMA | Giuseppe Gritti |
| 569 | Follicular Lymphoma | Fixed duration subcutaneous (SC) mosunetuzumab had better practice efficiency vs treat to progression epcoritamab SC in 3L+ follicular lymphoma (FL): an economic analysis | Esprit Ma |
| 570 | Follicular Lymphoma | Efficacy and Safety of Subcutaneous Mosunetuzumab Monotherapy and in Combination with Lenalidomide in Japanese Patients with Relapsed or Refractory Follicular Lymphoma | Dai Maruyama |
| 571 | Follicular Lymphoma | Nationwide Survey of the Journey of Patients Living with Follicular Lymphoma in China: Real-World Insights and Analysis | Yang He |
| 572 | Follicular Lymphoma | Patient-Reported Outcomes in Relapsed/Refractory Follicular Lymphoma Patients Treated With Epcoritamab: Overall and Subgroup Analysis by Baseline Symptom Burden | Patrick Connor Johnson |
| 573 | Follicular Lymphoma | Immunoglobulin Gene Rearrangements and Clonal Evolution as Prognostic Factors in B-NHL: A Novel Approach for Molecular Risk Stratification | Xiao Liu |
| 574 | Follicular Lymphoma | Real-World Outcomes and Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-cell Lymphoma - The GELTAMO experience | Mariana Bastos-Oreiro |
| 575 | Follicular Lymphoma | Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab | Ying Tian |
| 576 | Follicular Lymphoma | Fixed-duration subcutaneous mosunetuzumab had similar efficacy but lower cytokine release syndrome risk vs epcoritamab in 3L+ follicular lymphoma: an indirect comparison | Nilanjan Ghosh |
| 577 | Follicular Lymphoma | Treatment preferences of patients, caregivers, and physicians in follicular lymphoma: a global discrete-choice experiment study | Mitchell Smith |
| 578 | Follicular Lymphoma | Patterns of Chemoimmunotherapy Use and Outcomes in Relapsed/Refractory Follicular Lymphoma in the US Community Setting | John Burke |
| 579 | Follicular Lymphoma | A systematic review and meta-analysis of lenalidomide and anti-CD20 monoclonal antibody therapy in follicular lymphoma | Sarah Matarasso |
| 580 | Follicular Lymphoma | Clinical and pathological characteristics of high-grade B-cell lymphomas transformed from indolent lymphomas in HIV-negative and HIV-positive patients (pts) | Federico Erbella |
| 581 | Follicular Lymphoma | The Burden of Relapsed or Refractory Follicular Lymphoma in England: A Retrospective Analysis of Real-Word Treatment Patterns and Outcomes | Andrea Zaffalon |
| 582 | Follicular Lymphoma | EPCORITAMAB PLUS BENDAMUSTINE + RITUXIMAB (BR) FOR FIRST-LINE (1L) TREATMENT OF FOLLICULAR LYMPHOMA (FL): CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE NHL-2 ARM 3 | Stefano Luminari |
| 583 | Follicular Lymphoma | Comparative effectiveness of odronextamab versus real-world systemic therapies used in an external control arm in patients with relapsed/refractory follicular lymphoma |
Emmanuel Bachy |
Marginal zone and lymphoplasmacytic lymphoma
| Abstracts Book Number | Category | Title | First author |
| 584 | Marginal zone and lymphoplasmacytic lymphoma | Title: Extranodal Marginal Zone Non-Hodgkin Lymphoma Associated with Bronchial Mucosa (BALT Lymphoma): A 65-Year Experience from a Cancer Center | Raphael Cruz Seabra Prudente |
| 585 | Marginal zone and lymphoplasmacytic lymphoma | Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of elderly patients with indolent B-cell non-Hodgkin’s lymphoma | Shuchao Qin |
| 586 | Marginal zone and lymphoplasmacytic lymphoma | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma: an Open-label, Multicenter Study | Shuhua Yi |
| 587 | Marginal zone and lymphoplasmacytic lymphoma | Phase II study of orelabrutinib plus obinutuzumab with or without chemotherapy for marginal zone lymphoma patients with high-risk recurrence factors | Maogui Hu |
| 588 | Marginal zone and lymphoplasmacytic lymphoma | Short-course immunochemotherapy followed by sequential orelabrutinib in patients with high-risk marginal zone lymphoma | Fang Wei |
| 589 | Marginal zone and lymphoplasmacytic lymphoma | The Efficacy and Safety of Orelabrutinib‑Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Real-World Study | He Li |
| 590 | Marginal zone and lymphoplasmacytic lymphoma | Real world outcomes of the first-line treatment of localized extranodal marginal zone lymphoma of ocular adnexa or orbit | Juraj Ďuraš |
| 591 | Marginal zone and lymphoplasmacytic lymphoma | Novel Chemotherapy-Free Initial Treatment of Rituximab Plus Pegylated Interferon α-2b in Untreated Advanced Indolent B-Cell Lymphoma: 4-Year Follow-up Study | Huiqiang Huang |
| 592 | Marginal zone and lymphoplasmacytic lymphoma | Systemic MALT lymphoma with pulmonary involvement: A multi-institutional observational study in Japan | Kana Miyazaki |
| 593 | Marginal zone and lymphoplasmacytic lymphoma | Efficacy and safety of orelabrutinib plus obinutuzumab and lenalidomide in previously untreated marginal zone lymphoma: a single-arm, multicenter, phase II study | Wei Wang |
| 594 | Marginal zone and lymphoplasmacytic lymphoma | Multicenter retrospective cohort study of 805 patients with ocular adnexal marginal zone B-cell lymphoma on behalf of the Chinese Ocular Lymphoma Collaborative Group | Liang Wang |
| 595 | Marginal zone and lymphoplasmacytic lymphoma | Histological transformation (HT) in marginal zone lymphoma (MALT, nodal and splenic): risk, clinical features and outcome | Juan Gonzalo Correa |
| 596 | Marginal zone and lymphoplasmacytic lymphoma | The Burden of Relapsed or Refractory Follicular Lymphoma in England: A Retrospective Analysis of Real-Word Treatment Patterns and Outcomes | Andrea Zaffalon |
| 597 | Marginal zone and lymphoplasmacytic lymphoma | Orelabrutinib combined with anti-CD20 monoclonal antibodies is highly effective and well tolerated as first-line therapy for marginal zone B cell lymphoma | Liang Wang |
| 598 | Marginal zone and lymphoplasmacytic lymphoma | REdefining CLassification Algorithm and Staging System in Marginal Zone Lymphoma (RECLASS) | Côme Bommier |
| 599 | Marginal zone and lymphoplasmacytic lymphoma | Synergy of Venetoclax and Rituximab in Multiply Relapsed/Refractory Waldenström Macroglobulinaemia - a Case Series | Angeline Audrey Achola Josiah |
| 600 | Marginal zone and lymphoplasmacytic lymphoma | Features, Efficacy Analysis of 118 Cases of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia | Ou ou bai |
Mantle Cell Lymphoma
| Abstracts Book Number | Category | Title | First author |
| 601 | Mantle Cell Lymphoma | Targeting NAMPT and BTK in Mantle Cell Lymphoma: TP53-Dependent Synergistic Therapy | Na Li |
| 602 | Mantle Cell Lymphoma | Real-World Outcomes of Mantle Cell Lymphoma in Colombia: A Multicenter Cohort Study | Nicolas Duque-Clavijo |
| 603 | Mantle Cell Lymphoma | The efficacy and safety of zanubrutinib in combination with R-Chemo in the first-line treatment of patients with newly diagnosed mantle cell lymphoma | Haiwen Huang |
| 604 | Mantle Cell Lymphoma | Polatuzumab vedotin as an effective salvage therapy for relapsed/refractory mantle cell lymphoma resistantance to BTK and BCL inhibitors | Ping Yang |
| 605 | Mantle Cell Lymphoma | Refining treatment paradigms for Mantle Cell Lymphoma: a tailored approach | Won Seog Kim |
| 606 | Mantle Cell Lymphoma | REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS | Francis Nissen |
| 607 | Mantle Cell Lymphoma | Efficacy and Safety of Zanubrutinib Combined with Bendamustine and Rituximab as First-Line Treatment for Mantle Cell Lymphoma | Huayuan Zhu |
| 608 | Mantle Cell Lymphoma | Clinical Characteristics and Initial Treatment Patterns of Mantle Cell Lymphoma Patients in the BTKi Era: A Real-World Study | 海雯 黄 |
| 609 | Mantle Cell Lymphoma | Real-world treatment patterns, clinical outcomes and burden of illness of autologous stem-cell transplant ineligible patients with Mantle Cell Lymphoma in Ontario, Canada | Sandra Thibault |
| 610 | Mantle Cell Lymphoma | Relative Efficacy of Venetoclax plus Ibrutinib vs Bruton Tyrosine Kinase Inhibitor Monotherapy and Chemoimmunotherapy in Relapsed/Refractory Mantle Cell Lymphoma | Nilanjan Ghosh |
| 611 | Mantle Cell Lymphoma | Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma | Hui Wan |
| 612 | Mantle Cell Lymphoma | Factors Informing Optimal Management of Older Adults with Mantle Cell Lymphoma Amidst a Changing Therapeutic Landscape: Lessons from a 25-Year Institutional Experience | Pallawi Torka |
| 613 | Mantle Cell Lymphoma | Limited-stage mantle cell lymphoma: Clinical Features, Management, and Outcomes in a Multicenter Retrospective Study from Spain. | Silvia Del Rocio Verdesoto Cozzarelli |
| 614 | Mantle Cell Lymphoma | Long term follow-up of patients with mantle cell lymphoma, who underwent high-dose chemotherapy and autologous hematopoietic cell transplantation in first remission | Joanna Romejko-Jarosinska |
| 615 | Mantle Cell Lymphoma | IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY | Francesca Maria Quaglia |
| 616 | Mantle Cell Lymphoma | Real-world Burden of Disease (BoD), Treatment (tx) Patterns, and Outcomes in Patients with Mantle Cell Lymphoma (MCL) | Alvaro Alencar |
| 617 | Mantle Cell Lymphoma | Incidence and survival of mantle cell lymphoma (MCL) in England 2014-2021: a national cohort study from the UNCOVER Study Group | David Lewis |
| 618 | Mantle Cell Lymphoma | Sequential BTK inhibitor therapy in relapsed/refractory mantle cell lymphoma: Real-world outcomes and attrition rates – Final report from the Asia-Pacific registry | Hyungwoo Cho |
| 619 | Mantle Cell Lymphoma | Impact of ASCT consolidation and Rituximab Maintenance on Survival in Real-World patients with Mantle Cell Lymphoma (MCL) in Spain. The GELTAMO-MCL-2022 Study | Ana Marin-Niebla |
Aggressive B-cell Lymphomas
| Abstracts Book Number | Category | Title | First author |
| 620 | Aggressive B-cell Lymphomas | A standardized process for a rapid dose escalation of epcoritamab for patients with lymphoid malignancies in the United States | Kelsey Baron |
| 621 | Aggressive B-cell Lymphomas | Efficacy and Safety of Glofitamab Combined with Tislelizumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma: A pilot study in China | Hongyan Tong |
| 622 | Aggressive B-cell Lymphomas | P+R-ICE: Pembrolizumab in combination with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) | Louise Stanton |
| 623 | Aggressive B-cell Lymphomas | ORELABRUTINIB PLUS LENALIDOMIDE AND RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE-B CELL LYMPHOMA | Hui Liu |
| 624 | Aggressive B-cell Lymphomas | The CMOP±R Regimen Shows High Efficacy As a First-Line Treatment For NHL: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis | Haiwen Huang |
| 625 | Aggressive B-cell Lymphomas | Outpatient administration of epcoritamab (epcor) monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Update from EPCORE NHL-6 | Rakhee Vaidya |
| 626 | Aggressive B-cell Lymphomas | Australian patients with relapsed or refractory diffuse large B-cell lymphoma frequently fail eligibility criteria for landmark and registration clinical trials | Eliza Hawkes |
| 627 | Aggressive B-cell Lymphomas | Promising outcomes with Pola-R-CHP in newly diagnosed Diffuse large B cell lymphoma with bulky disease. | Zhiping Jiang |
| 628 | Aggressive B-cell Lymphomas | Treatment-related infections and clinical outcomes of Diffuse Large B-Cell Lymphoma treated with polatuzumab vedotin-based combination therapy | wenyu Li |
| 629 | Aggressive B-cell Lymphomas | Efficacy and Safety Analysis of CAR-T Cell Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma After Failure of Bispecific Antibody Treatment | Liang Wang |
| 630 | Aggressive B-cell Lymphomas | Polatuzumab vedotin-Based Combination Therapy Demonstrates Efficacy and Safety in Elderly Diffuse Large B-Cell Lymphoma Patients | Wei Guo |
| 631 | Aggressive B-cell Lymphomas | Efficacy of Pola-R-CHP in Previously Untreated CD5-Positive Diffuse Large B-Cell Lymphoma | Junqing Xu |
| 632 | Aggressive B-cell Lymphomas | Efficacy and Safety of Pola-ICE, with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Single Center Study | Xuanye Zhang |
| 633 | Aggressive B-cell Lymphomas | Polatuzumab vedotin improves efficacy and survival in newly diagnosed advanced diffuse large B-cell lymphoma: A multicenter retrospective analysis | Jianxia He |
| 634 | Aggressive B-cell Lymphomas | Optimal treatment for double-expressor lymphoma in the era of novel agents: a systematic review and meta-analysis | Minyue Zhang |
| 635 | Aggressive B-cell Lymphomas | Symptom Burden and Health-Related Quality of Life in Patients with Aggressive Non-Hodgkin Lymphoma in China: A Cross-Sectional Study | Jie - Liu |
| 636 | Aggressive B-cell Lymphomas | Glofitamab Combined with Salvage Therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Real-World Prospective Observational Study in Chinese Patients | Haiwen Huang |
| 637 | Aggressive B-cell Lymphomas | The non-standard role of bispecific antibodies in the treatment algorithm of Relapsed/Refractory DLBCL in countries without CART. Argentine experience with epcoritamab | Carolina Mahuad |
| 638 | Aggressive B-cell Lymphomas | Impact of First-Line Setting Maintenance Therapy on Prognosis in Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study | Liang Wang |
| 639 | Aggressive B-cell Lymphomas | DIFFUSE LARGE B CELL LYMPHOMA: A TUNISIAN MULTICENTER EXPERIENCE. | Mohamed Adnene LAATIRI |
| 640 | Aggressive B-cell Lymphomas | Efficacy of Zanubrutinib Plus R-CHOP Versus R-CHOP Alone in Newly Diagnosed Intravascular Large B-Cell Lymphoma: A Retrospective Study | Chao Chen |
| 641 | Aggressive B-cell Lymphomas | Outcomes of dose adjusted R-EPOCH in Elderly Patients: A Retrospective Study | Guneet Kaleka |
| 642 | Aggressive B-cell Lymphomas | Real-World Efficacy and Safety of Glofitamab in Chinese Patients with R/R DLBCL: High Response Rates in High-Risk Populations | Zhengzi Qian |
| 643 | Aggressive B-cell Lymphomas | Polatuzumab Vedotin with BTK Inhibitors and Chemotherapy Shows Rapid, Deep Responses in Non-GCB Diffuse Large B-Cell Lymphoma | Yi Xia |
| 644 | Aggressive B-cell Lymphomas | Efficacy of Zanubrutinib in Newly Diagnosed MYD88-Mutated Diffuse Large B-cell Lymphoma: A Retrospective Single-center Real-world Study | Wenrong Huang |
| 645 | Aggressive B-cell Lymphomas | Real-world treatment patterns and survival outcomes of Diffuse Large B Cell Lymphoma: a retrospective analysis from a Comprehensive Portuguese Cancer Center | Inês Oliveira Ramos |
| 646 | Aggressive B-cell Lymphomas | Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2 | Min Zhang |
| 647 | Aggressive B-cell Lymphomas | Safety and Efficacy of Glofitamab in Relapsed/Refractory Diffuse Large B cell lymphoma -Data from Real-World Study. | David Belada |
| 648 | Aggressive B-cell Lymphomas | Real-World Outcomes of Second-Line Therapies in Relapsed/Refractory DLBCL Patients in Germany: Impact of Front-Line Treatment-Free Period (2020-2022) | Guillaume Azarias |
| 649 | Aggressive B-cell Lymphomas | Responses, overal survival and toxicity in adult patients with Burkitt Lymphoma treated with the BURKIMAB-13 protocol Data of two institutions in Argentina. | Luciana Andrea Guanchiale |
| 650 | Aggressive B-cell Lymphomas | Efficacy of Pola-R-CHP in Patients with Newly Diagnosed DLBCL: A Retrospective Analysis of Real-world Data | Shenmiao Yang |
| 651 | Aggressive B-cell Lymphomas | Utility of Geriatric Assessment Tools to Predict Chemotoxicity Amongst Elderly patients with DLBCL | LM Poon |
| 652 | Aggressive B-cell Lymphomas | Effectiveness and Safety of Pola-R-CHP Regimen in Previously Untreated Low-risk DLBCL: A Nationwide Multicenter Retrospective Study of IPI 0-1 Patients in China | Yuhong Ren |
| 653 | Aggressive B-cell Lymphomas | Effectiveness and Genomic Landscape of Front-Line Polatuzumab-Based Regimens in Diffuse Large B-Cell Lymphoma: A Real-World Single-Center Study on TP53-Mutated Subgroups | Jia Liu |
| 654 | Aggressive B-cell Lymphomas | Predictive Value of Extranodal Involvement on Clinical Outcomes and Toxicities in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following CAR-T Cell Therapy | Safia BELBACHIR |
| 655 | Aggressive B-cell Lymphomas | Pola-R-CHP Performed Well in POLARIX Trial-ineligible and Low Risk (IPI 0-1) Patients with Previously Untreated DLBCL: A Prospective Observational Study | Yuhong Ren |
| 656 | Aggressive B-cell Lymphomas | Real-world Treatment Patterns, Costs, and Survival Among Medicare Patients with Relapsed/Refractory DLBCL Receiving Third-Line Therapy | Mugdha Gokhale |
| 657 | Aggressive B-cell Lymphomas | Transplantation in combination with CAR-T therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy | Kai Hu |
| 658 | Aggressive B-cell Lymphomas | Response to epcoritamab correlateds with higher ALC/AMC ratio: insights from a realworldretrospective analysis | Yuwen Wang |
| 659 | Aggressive B-cell Lymphomas | Treatment Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients With High Cardiovascular Risk and Treated With Non-Anthracycline–Containing Regimens | Justin Darrah |
| 660 | Aggressive B-cell Lymphomas | Impact of Healthcare Setting on Diffuse Large B-Cell Lymphoma(DLBCL) Outcomes- A Real-World Comparative Study | Purnima Sravanti Teegavarapu |
| 661 | Aggressive B-cell Lymphomas | Long-term Follow-up of Response-Driven, Dose-Intensified Immunochemotherapy ± ASCT in High-Risk Aggressive B-Cell Lymphoma: Update from a Single-Center Experience | Ting Xie |
| 662 | Aggressive B-cell Lymphomas | Outcomes with CAR-T and subsequent therapies in patients with T cell histiocyte-rich large B-cell lymphoma, UK experience | Dima El Sharkawi |
| 663 | Aggressive B-cell Lymphomas | Patient Preferences for Attributes of Bispecific Antibodies Indicated for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States | Erin Mulvey |
| 664 | Aggressive B-cell Lymphomas | Simplified Molecular IPI as Eligibility Criteria for Clinical Trials: Analysis of the Turkish Lymphoma Study Group’s Large B-Cell Lymphoma Cohort | Umut Yılmaz |
| 665 | Aggressive B-cell Lymphomas | Real World Outcomes of Diffuse Large B Cell Lymphoma in Brazil confirm the prognostic impact of Cell of Origin: BRA-DLBCL Multicenter Retrospective Study. | Guilherme Fleury Perini |
| 666 | Aggressive B-cell Lymphomas | Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in an Asian multiethnic cohort | Nicole-Ann Lim |
| 667 | Aggressive B-cell Lymphomas | Real-world safety and efficacy of epcoritamab for patients with relapsed/refractory large B-cell lymphomas | Allison M. Bock |
| 668 | Aggressive B-cell Lymphomas | Real-World Evidence of Second-Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter GELTAMO Study | Leyre Bento |
| 669 | Aggressive B-cell Lymphomas | Feasibility of 2nd-line CAR-T cell therapy after early failure of Polatuzumab-containing 1st-line chemoimmunotherapy in patients with diffuse large B-cell lymphoma | Maria-Luisa Schubert |
| 670 | Aggressive B-cell Lymphomas | Outcome of Second-Line Axicabtagene Ciloleucel in Relapsed/Refractory Large B-Cell Lymphoma patients: Real-World Analysis in the DACH area (Germany, Austria, Switzerland) | Simon Call |
| 671 | Aggressive B-cell Lymphomas | Glofitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), a Real-World Evidence Study from the CUBIC Consortium | Geoffrey Shouse |
| 672 | Aggressive B-cell Lymphomas | Real-World Data of Lisocabtagene Maraleucel as Second Line Therapy for Patients with Large B-cell Lymphoma: First Results of the French DESCAR-T Registry by LYSA | Gabriel BRISOU |
| 673 | Aggressive B-cell Lymphomas | Prognostic factors and outcomes in patients with late relapse Diffuse Large B-cell Lymphoma treated with second-line chemotherapy and autologous stem cell transplantation | Jing Yuan Tan |
| 674 | Aggressive B-cell Lymphomas | Clinicopathological Characteristics, Treatment Response, and Prognostic Factors of Patients with Intravascular Large B Cell lymphoma: A Multicenter Study in China | Jingsong He |
| 675 | Aggressive B-cell Lymphomas | A combined EASIX-IPI (E-IPI) score improves the prognostic stratification of newly diagnosed Diffuse large B-cell Lymphoma (DLBCL) | Jing Yuan Tan |
| 676 | Aggressive B-cell Lymphomas | Low albumin correlates with poor prognosis in patients with relapsed/refractory Aggressive B-cell Lymphoma ineligible for autologous stem cell transplant | Louise Pettersson |
| 677 | Aggressive B-cell Lymphomas | Dynamic Changes of Absolute CD4 Count in Peripheral Blood as a Predictor of Efficacy in Refractory/Relapsed DLBCL Harboring TP53 Gene MutationsTreated with Glofitamab | Xia Zhao |
| 678 | Aggressive B-cell Lymphomas | Immune dysregulation in Diffuse Large B-cell Lymphoma (DLBCL)/High-Grade B-CellLymphoma (HGBL) with MYC alterations: Comparative Analysis of R-CHOP versus R-DA-EPOCH | Nicolas De Lucas Torres |
| 679 | Aggressive B-cell Lymphomas | Frequency of CD30 Expression and prognostic impact in Patients with Diffuse Large B-Cell Lymphoma | Marcelo Bellesso |
| 680 | Aggressive B-cell Lymphomas | Bone Marrow Iron Levels and Iron Supplementation: Prognostic Outcomes in de novo DLBCL Patients | Mikko Chan |
| 681 | Aggressive B-cell Lymphomas | Combined Pre-treatment Levels of Surface TREM1 on Neutrophils and Surface TREM2 on M-MDSCs Predict Early Mortality Within One Year Post-Diagnosis in DLBCL Patients | Hao-Yuan Wang |
| 682 | Aggressive B-cell Lymphomas | HIGH GRADE B-CELL LYMPHOMA (HG-BL) WITH BLASTOID MORPHOLOGY – SUDDEN INCREASE IN INCIDENCE OF A RARE ENTITY | Ivana Ilić |
| 683 | Aggressive B-cell Lymphomas | Selinexor in combination with R-EPOCH for patients with previously untreated HIV-associated DLBCL: A single-center, prospective, single-arm trial | Chaoyu Wang |
| 684 | Aggressive B-cell Lymphomas | Mecapegfilgrastim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial | Jie Wang |
| 685 | Aggressive B-cell Lymphomas | Drug Prescriptions for Peripheral Neuropathy and Gastrointestinal Events in First-Line Pola-R-CHP for Elderly DLBCL Patients Including Those Aged 80+ in Japan | Yo Saito |
| 686 | Aggressive B-cell Lymphomas | Tabelecleucel in EBV positive post-transplant lymphoproliferative disease: a real word experience | Anna Maria Barbui |
| 687 | Aggressive B-cell Lymphomas | Outcomes in Patients with Post-transplant Lymphoproliferative Disorder: The Virginia Commonwealth University Experience | Samir Hussaini |
| 688 | Aggressive B-cell Lymphomas | Intravenous middle-dose methotrexate incorporated into R-CHOP prevented central nervous system relapse in high‐risk diffuse large B-cell lymphoma patients | Min Lang |
| 689 | Aggressive B-cell Lymphomas | How to Optimize the Use of High-Cost Therapies in DLBCL: A Collaborative Observational Study by the Uruguayan Lymphoma Group | Maria Victoria Irigoin |
| 690 | Aggressive B-cell Lymphomas | THE PROGNOSTIC ROLE OF EBV IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: A RETROSPECTIVE SINGLE CENTER ANALYSIS | Periana Minga |
| 691 | Aggressive B-cell Lymphomas | Analysis of Brentuximab Vedotin use in the setting of adults patients with Post-transplant lymphoproliferative disorders among The French national K-virogref database. | Fontanet BIJOU |
| 692 | Aggressive B-cell Lymphomas | POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: an International registry study (the PLATO Study) | Tetiana Skrypets |
CNS Lymphomas
| Abstracts Book Number | Category | Title | First author |
| 693 | CNS Lymphomas | MATRix regimen for newly diagnosed Primary Large B-cell lymphoma of immune-privileged sites, arising in CNS (PCNS-LBCL) and vitreoretinal (PVR-LBCL): outcome and toxicity | Maria Bouzani |
| 694 | CNS Lymphomas | The Efficacy and Safety of Orelabrutinib, Rituximab and High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma: A Retrospective Study | Shujuan Wen |
| 695 | CNS Lymphomas | Clinical Response and Safety for Relapsed/Refractory Central Nervous System Diffuse Large B Cell Lymphoma Treated By Radiotherapy sequential Glofitmab | juan Huang |
| 696 | CNS Lymphomas | Outcome Disparities in Primary CNS Lymphoma: A Retrospective Analysis at an Academic Center with a Predominantly Hispanic Patient Population | Yeshanew Teklie |
| 697 | CNS Lymphomas | Novel Small Molecular Target Agents with HD-MTX-Based Regimens Improved Remission Rates without Prolonging PFS in Newly Diagnosed PCNSL | Huiying Zhu |
| 698 | CNS Lymphomas | A Novel Prognostic Model for Predicting Disease Progression and Survival in Primary Large B-Cell Lymphoma of Immune-Privileged Sites | Ganggang Wang |
| 699 | CNS Lymphomas | Exploration of the optimal treatment modality for vitreoretinal lymphoma: a PRISMA compliant meta-analysis and systematic review | Liang Wang |
| 700 | CNS Lymphomas | Orelabrutinib plus semustine, temozolomide and lenalidomide (BMeTL) regimen with sequential maintenance treatment in elderly or frail patients with CNSL: a phase II study | Hongwei Xue |
| 701 | CNS Lymphomas | Efficacy of High-Dose Thiotepa, Rituximab, and Pomalidomide as a Salvage Regimen for Relapsed/Refractory Primary Central Nervous System Lymphoma | Xia Zhao |
| 702 | CNS Lymphomas | Oral lenalidomide or BTK inhibitors as Maintenance Therapy showed durable efficacy after the first Remission in PCNSL patients | Zhangyuting He |
| 703 | CNS Lymphomas | Diagnosis of central nervous system B lymphoma using methylome marker detected by CSF dPCR | Bernard Drénou |
| 704 | CNS Lymphomas | Orelabrutinib plus rituximab and high-dose methotrexate in primary central nervous system diffused large B-cell lymphoma: a single-arm phase II study | Liling Zhang |
| 705 | CNS Lymphomas | Point of care anti-CD19 CART cells for primary and secondary CNS lymphoma – the experience of a single center cohort | Ronit Marcus |
| 706 | CNS Lymphomas | Zanubrutinib, Temozolomide, and Rituximab (ZRT) Show Efficacy in refractory or relapsed Primary central nervous system lymphoma | wenyu shi |
| 707 | CNS Lymphomas | Clinical outcomes with Bispecific antibodies in the Management of Secondary Central Nervous System Lymphoma | Nikita K Dave |
| 708 | CNS Lymphomas | Planned-use glucarpidase for outpatient high dose methotrexate (HD-MTX) in patients with CNS lymphoma | Lauren R. Schaff |
| 709 | CNS Lymphomas | Strikingly reduced toxicities of fotemustine-based chemotherapeutics than high-dose methotrexate-containing regimens with comparable efficacy | Xudong Zhang |
| 710 | CNS Lymphomas | First-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL | Zengjun Li |
| 711 | CNS Lymphomas | Planned glucarpidase for CNS lymphoma patients at high risk of methotrexate (MTX) toxicity | Lauren R. Schaff |
| 712 | CNS Lymphomas | Unraveling the Role of MIF/CD74 Axis in Primary Central Nervous System Lymphoma | Jiazhu Wu |
| 713 | CNS Lymphomas | Chemotherapy-free therapy with rituximab, lenalidomide, and poseltinib in relapsed or refractory primary central nervous system lymphoma: a multi-center, phase II study | Dong Hyun Kim |
| 714 | CNS Lymphomas | CART Cell Therapy in the Management of Secondary Central Nervous System Lymphoma | Nikita K Dave |
| 715 | CNS Lymphomas | Low-Intensity Focused Ultrasound Enhances CD20 Antibody Delivery Across BBB in CNS Lymphoma | Juan Huang |
| 716 | CNS Lymphomas | CD19-directed chimeric antigen receptor (CART)-cell therapy for B-cell lymphomas with primary or secondary CNS involvement. Real-world data from a multicenter analysis | Vladan Vucinic |
| 717 | CNS Lymphomas | Leptomeningeal Disease is Associated With MYC Chromosomal Alterations and Worse Overall Survival Among Secondary CNS Lymphoma Patients Treated With Salvage Radiotherapy | Gustav Cederquist |
Hodgkin Lymphoma
| Abstracts Book Number | Category | Title | First author |
| 718 | Hodgkin Lymphoma | Aggressive clinical features and poor outcome may associate with decreased immune function in HIV positive HL in the cART era: A multicenter study from China | Chaoyu Wang |
| 719 | Hodgkin Lymphoma | Brentuximab Vedotin plus sintilimab for relapsed classical Hodgkin lymphoma patients without ASCT | Zhihe Liu |
| 720 | Hodgkin Lymphoma | The Treatment Evolution of Classic Hodgkin Lymphoma over Two Decades in China: Real-world Experiences of An Academic Center | Zhangyuting He |
| 721 | Hodgkin Lymphoma | Tislelizumab combined with CPEL (Chidamide, Prednisone, Etoposide, Lenalidomide) Followed Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Hodgkin Lymphoma | Yawen Wang |
| 722 | Hodgkin Lymphoma | Hodgkin Lymphoma: Are We Leaving Patients in "Check"? | Inês Oliveira Ramos |
| 723 | Hodgkin Lymphoma | Vanishing bile duct syndrome in Hodgkin’s Lymphoma: A Case Series from Hospitals in the Community of Madrid | Maria Garcia Roa |
| 724 | Hodgkin Lymphoma | Treatment and outcomes of patients with relapsed Hodgkin's Lympoma after autologus stem cells transplantation. | Natalya Milanovich |
| 725 | Hodgkin Lymphoma | Conventional Chemotherapy Remains Effective in Relapsed and Primary Refractory Classical Hodgkin Lymphoma in the Era of Novel Agents: A Single-Institution Experience | Marianne LY Tan |
| 726 | Hodgkin Lymphoma | Hodgkin's Lymphoma Treatment Optimization: Perspectives from Uruguay and Resource-Limited Countries | Ana Carolina Oliver |
| 727 | Hodgkin Lymphoma | Do patients with classic Hodgkin Lymphoma treated with ABVD in low-middle income countries have a higher risk of neutropenia/febrile neutropenia without G-CSF support? | Bárbara Ferreira Cordeiro Galvão |
| 728 | Hodgkin Lymphoma | Molecular Mechanisms Involved in the Pathogenesis of Post Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma | Muhit Ozcan |
| 729 | Hodgkin Lymphoma | Experience with VECADD In Advanced classic Hodgkin Lymphoma In Pregnant And Non-pregnant Female Patients | Anne Sophie Robertz |
| 730 | Hodgkin Lymphoma | Results of prospective observational study of pembolizumab biosimilar BCD-201 in patients with refractory classical Hodgkin’s Lymphoma | Elias Antonio Gracia Medina |
| 731 | Hodgkin Lymphoma | Brentuximab Vedotin (Bv)+Avd In Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma: An Italian Real-Life Multicentric Study | Ilaria Del Giudice |
| 732 | Hodgkin Lymphoma | Extended Brentuximab Vedotin Lead-In and Abbreviated AVD in Older Patients (>60 years) with Advanced Hodgkin Lymphoma (HL) and High Comorbidity (ECOG≥2 and/or CIRS-G>10) | Annarosa Cuccaro |
| 733 | Hodgkin Lymphoma | Active surveillance is a valid option for newly diagnosed nodular lymphocyte-predominant Hodgkin Lymphoma. | John Apostolidis |
| 734 | Hodgkin Lymphoma | Real-World Outcomes of Frontline Brentuximab Vedotin in Older Patients with Classical Hodgkin Lymphoma -An International, Multi-Center Study | Efrat Luttwak |
| 735 | Hodgkin Lymphoma | Outcomes in Double-Exposed Classical Hodgkin Lymphoma: Impact of Treatment Sequence and Salvage Strategies After Brentuximab Vedotin and Checkpoint Inhibitor Failure | Massimiliano Marinoni |
| 736 | Hodgkin Lymphoma | Efficacy of Dose Escalation to BEACOP-DAC vs. Continuation of ABVD in Hodgkin’s Lymphoma Patients with Interim PET Deauville Score of 4 | Andre Costa Meireles |
| 737 | Hodgkin Lymphoma | Cost implications of reproductive outcomes in Hodgkin’s Lymphoma patients receiving first-line treatment from the Denmark national healthcare and societal perspectives | Alexa Molinari |
NK/T-cell Lymphomas
| Abstracts Book Number | Category | Title | First author |
| 738 | NK/T-cell Lymphomas | Surfaceome Profiling for the Identification of Novel Immunotherapeutic Targets in Natural Killer/T cell Lymphoma (NKTL) | Ern Sen Chew |
| 739 | NK/T-cell Lymphomas | Addressing Hypercalcemia in Adult T-cell Leukemia/Lymphoma | Maya Srinivasan |
| 740 | NK/T-cell Lymphomas | Real world outcomes of histone deacetylase inhibitors in relapsed/ refractory peripheral T cell lymphoma: a multicentric retrospective study in Argentina | Laura Korin |
| 741 | NK/T-cell Lymphomas | A Novel Model for Predicting Survival Outcomes of Patients with Angioimmunoblastic T Cell Lymphoma: A Real-World Study from Multi-centers in China | Xia Zhao |
| 742 | NK/T-cell Lymphomas | Outcome of patients with T-cell/histiocyte-rich large B-cell lymphoma: A single institution series | John Apostolidis |
| 743 | NK/T-cell Lymphomas | Role of Consolidation after Brentuximab Vedotin Treatment in Relapsed/Refractory Mycosis Fungoides: Polish Lymphoma Research Group (PLRG) Retrospective Multicenter Study | Ewa Chmielowska |
| 744 | NK/T-cell Lymphomas | Impact of Relative Dose Intensity of Chemotherapy in Elderly Patients with Extranodal NK/T-Cell Lymphoma | Wanyue Zhao |
| 745 | NK/T-cell Lymphomas | Clinical Outcomes and Prognostic Factors in Extranodal NK/T-Cell Lymphoma: A 12-Year Retrospective Study from a Single Center | Haiwen Huang |
| 746 | NK/T-cell Lymphomas | Targeting Arginine Methyltransferase PRMT5 as a Promising Therapeutic Strategy in NKTCL | Siyu Qian |
| 747 | NK/T-cell Lymphomas | Central nervous system involvement in extranodal natural killer/T-cell lymphoma: a retrospective study of a consecutive 13-year case series | Liang Wang |
| 748 | NK/T-cell Lymphomas | Effectiveness and Safety of Linperlisib in Patients with Mature T/NK-Cell Lymphoma: A Real-World retrospective Study | Zhiming Li |
| 749 | NK/T-cell Lymphomas | AUTOLOGOUS VS. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOBLASTIC LYMPHOMA | haiwen Huang |
| 750 | NK/T-cell Lymphomas | Golidocitinib Monotherapy in the Treatment of Refractory / Relapsed Indolent T/NK-Cell Lymphoma: Preliminary Results from T-LGLL Cohort | Ying Yu |
| 751 | NK/T-cell Lymphomas | Golidocitinib Combined with CHOP in Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from a Phase 1/2 Clinical Trial | Wei Zhang |
| 752 | NK/T-cell Lymphomas | SAFETY AND EFFICACY OF BRENTUXIMAB VEDOTIN IN CHINESE ADULTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF BRAVE STUDY | Wei-Li Zhao |
| 753 | NK/T-cell Lymphomas | Final Analysis of Concordance Study of Immunohistochemical CD30 Expression Detected by Nine Assays and the Ventana CD30 Assay in Chinese Lymphoma Patients (CREDIT Study) | Xiang-Nan Jiang |
| 754 | NK/T-cell Lymphomas | Real world patient characteristics, treatment patterns, and outcomes for Chinese patients with CD30-positive peripheral T-cell lymphoma | Xiaojing Yan |
| 755 | NK/T-cell Lymphomas | Dual TRBC1 and TRBC2 staining for Rapid Clonality Testing in T-Cell Lymphomas by Flow Cytometry: A Preliminary Single Center Analysis |
Silvia Bellesi |
| 756 | NK/T-cell Lymphomas | Real-World Study of Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T Cell Lymphoma: Retrospective Data from Medical Centers in China | Yan Gao |
| 757 | NK/T-cell Lymphomas | Incidence of Myeloid Neoplasms in Patients with T-Follicular Helper Cell Lymphomas (TFHCL) | Kai Shiang Lin |
| 758 | NK/T-cell Lymphomas | Clinical outcomes of allogeneic hematopoietic stem cell transplantation in patients with hepatosplenic T-cell lymphoma | Zhuoxin Zhang |
| 759 | NK/T-cell Lymphomas | Updated Outcomes of P-GEMD in Treatment- naïve Early-stage Non-Upper Aero-Digestive Tract or Advanced-stage Extranodal NK/T Cell Lymphoma | Jinhua Liang |
| 760 | NK/T-cell Lymphomas | Novel CTCL Risk Stratifier Integrating Lymph Node Volumetrics and mSWAT to Predict Survival and Therapy Response | Larisa J. Geskin |
| 761 | NK/T-cell Lymphomas | Survival Outcomes in Nodal Peripheral T-cell Lymphoma following Primary and Second-line Treatment: An Australasian-Canadian Collaborative Study | Chathuri Abeyakoon |
| 762 | NK/T-cell Lymphomas | Artificial Intelligence-assisted Quantitative Analysis for the Immunohistochemical Expression of CD30 in Lymphomas | Xiang-Nan Jiang |
| 763 | NK/T-cell Lymphomas | CD4+ CADM1+ T Cell Population Emerges as a Malignancy-Associated Biomarker in EBV-related Lymphoproliferative Disorders | Qinhuan Luo |
| 764 | NK/T-cell Lymphomas | Real-World Outcomes of Mitoxantrone Hydrochloride Liposome Regimen for Peripheral T-Cell Lymphoma: The Efficacy and Safety Analysis of Treatment-naïve Population (MOMENT) | Donglu Zhao |
| 765 | NK/T-cell Lymphomas | Combination of liposomal mitoxantrone with cyclophosphamide, vincristine, and prednisone (CMOP) in treatment-naïve PTCLs: a multicenter, single-arm, phase Ib study | Huiqiang Huang |
| 766 | NK/T-cell Lymphomas | Outcomes of Patients with Peripheral T-cell Lymphoma by Race/Ethnicity and Clinical Trial Enrollment | Alexander D. Sanjurjo |
Multiple Myeloma
| Abstracts Book Number | Category | Title | First author |
| 767 | Multiple Myeloma | Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severerenal failure requiring hemodialysis. A single-center experience | Iuliia Kliuchagina |
| 768 | Multiple Myeloma | Efficacy and Safety of Selinexor-melphalan Combined Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma | Shuai Su |
| 769 | Multiple Myeloma | Comparative Study on Re-treatment for First Relapse after Proteasome Inhibitor Therapy in Multiple Myeloma | Yu 钰 Feng |
| 770 | Multiple Myeloma | QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS: REAL-WORLD STUDY IN KAZAKHSTAN | Azaliya Turgunova |
| 771 | Multiple Myeloma | Treatment outcomes in patients with newly diagnosed multiple myeloma complicated by severe renal failure requiring hemodialysis | Iuliia Kliuchagina |
| 772 | Multiple Myeloma | Increased efficacy of stem cell mobilization with cytarabine + G-CSF compared to cyclophosphamide + G-CSF and plerixafor + G-CSF in poor mobilizers | Svetlana Elkhova |
| 773 | Multiple Myeloma | Efficacy and safety of selinexor, carfilzomib, pomalidomide and dexamethasone in the treatment of MM with extramedullary disease: a prospective multi-center study | Hai Zhou |
| 774 | Multiple Myeloma | SOX4-PRUNE1-IGF2BP3-SLC2A1 Axis Promotes Proliferation in Multiple Myeloma with 1q21 Gain | Yawen Wang |
| 775 | Multiple Myeloma | STING Drives Multiple Myeloma Progression via Cell Cycle Dysregulation and Apoptosis Suppression | Chunlan Huang |
| 776 | Multiple Myeloma | Prognostic Risk Stratification Model for Multiple Myeloma Based on Group-Based Trajectory Modeling | Wenjiao Tang |
| 777 | Multiple Myeloma | Intensified Cyclophosphamide, Bortezomib, Dexamethasone (iCyBorD) for the treatment of newly diagnosed Multiple Myeloma with Acute Kidney Injury | Guneet Kaleka |
Cellular therapies
| Abstracts Book Number | Category | Title | First author |
| 778 | Cellular therapies | The importance of inflammatory biomarkers in predicting response to CAR-T in patients with lymphoma. | Nicolas De Lucas Torres |
| 779 | Cellular therapies | PEG-rhG-CSF versus rhG-CSF in treating neutropenia after CAR-T cell therapy for patients with B cell lymphoma | Di Wang |
| 780 | Cellular therapies | Deaths in patients in complete remission with CAR T therapy. Toxicity into account? | Silvia Sequero Lopez |
| 781 | Cellular therapies | Impact of obesity and overweight on outcomes of patients with B-cell lymphomas and multiple myeloma treated with CAR-T cells: a systematic review and meta-analysis | Marília Gomes |
| 782 | Cellular therapies | Game set and MATCH for CAR-T in DLBCL? Why treatment bias against bispecific antibodies may make matched real-world comparisons uninterpretable | Amy Alexandra Kirkwood |
| 783 | Cellular therapies | Place-of-Care Produced Fresh Formulation MB-CART19.1 Cell Therapy for Relapsed or Refractory CD19+ Hematological Malignancies with Central Nervous System involvement | Skirmante Cernauskiene |
| 784 | Cellular therapies | Impact on health outcomes of treating all eligible patients with axicabtagene ciloleucel in Portugal – a modeling approach | Filipa de Aragão |
| 785 | Cellular therapies | Hematologic Toxicity Analysis of CAR-T Cell Therapy: A Retrospective Real-World Study | Liang Wang |
| 786 | Cellular therapies | Towards One Week Vein-to-Vein Time of Place-of-Care Produced Fresh Formulation CAR-T CD19 Therapy | Adomas Bukauskas |
| 787 | Cellular therapies | A closer look at secondary malignancies post CART – is the risk real? | Hannah Schulze |
| 788 | Cellular therapies | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial | Liang Wang |
| 789 | Cellular therapies | A Clinical Risk Scoring System for the Prediction of Early Infection after CAR-T Therapy | Ning An |
| 790 | Cellular therapies | Bridging Therapy in CAR-T Cell Management of Relapsed/Refractory Lymphoma: Balancing Disease Control and Infusion Delays in High-Risk Cohorts | Liang Wang |
| 791 | Cellular therapies | Improved Outcomes with CAR-T Cell Therapy in R/R Transformed Follicular Lymphoma Compared to R/R De-Novo DLBCL : A single-center experience | Safia BELBACHIR |
| 792 | Cellular therapies | Infusion stays and costs for patients treated with axi-cel or liso-cel for second-line large B-cell lymphoma in France: differences from comprehensive hospital databases | Catherine Thieblemont |
| 793 | Cellular therapies | Comparison of Mortality and Disease Progression between Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager using the FDA Adverse Event Reporting System | Noah Giese |
| 794 | Cellular therapies | Patient-reported adverse events (AEs) and health-related quality of life (HRQoL) by CAR T-cell product in patients with aggressive B-cell lymphomas | Alice Di Rocco |
| 795 | Cellular therapies | AUC fludarabine and product choice are main predictors of CRS/ICANS after CAR T cell therapy: generation of an improved model | Keven Hoerster |
| 796 | Cellular therapies | Serum and Deep-Learning-Based MRI Biomarkers of Neurotoxicity and Survival Implications After Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma | Ankey Zhu |
| 797 | Cellular therapies | DALY 1: A phase I safety, dose finding and feasibility trial of zamtocabtagene autoleucel (MB-CART2019.1) in patients with r/r B-NHL: 5Y Follow-up report | Peter Borchmann |
Experimental therapeutics
| Abstracts Book Number | Category | Title | First author |
| 798 | Experimental therapeutics | Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma | Xiaohui Wang |
| 799 | Experimental therapeutics | MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides | Emmanuella Guenova |
| 800 | Experimental therapeutics | Therapeutic potential of NRF2 inhibition in Chronic lymphocytic leukemia and in combination with current therapy | Sara Duarte |
| 801 | Experimental therapeutics | As a novel epigenetic modulator, EZH1/2 dual inhibitor HM97662 exhibits antitumor efficacy in hematological malignancies and overcomes EZH2-inhibitor mediated resistance | Jooyun Byun |
| 802 | Experimental therapeutics | A Study on the Mechanism of the Novel Highly Selective HDAC Inhibitor Purinostat Mesylate in Double-hit Lymphoma and Its Therapeutic Potential Combination with Venetoclax | Jie Wang |
| 803 | Experimental therapeutics | Polatuzumab vedotin and glofitamab: a synergistic approach to anti-tumor activity | Alessia Bottos |
| 804 | Experimental therapeutics | Preclinical Evaluation of GCC2005, A Novel Allogenic CD5 CAR-NK Cell Therapy, for T-cell Malignancies | Jaeho Guk |
| 805 | Experimental therapeutics | Pre-clinical development of CAR-T cells targeting a lytic EBV antigen gp350 for therapy of EBV-positive diffuse large B-cell lymphoma | Yan-Li Li |
| 806 | Experimental therapeutics | ARV-393, a PROTAC BCL6 degrader, in preclinical models of diffuse large B-cell lymphoma, nodal T-follicular helper cell lymphoma, and transformed follicular lymphoma | Anna Van Acker |
| 807 | Experimental therapeutics | TENT5C as a target of chromatin remodeler SMARCA2 participates BTK inhibitor resistance in mantle cell lymphoma by regulating ATP metabolism | Yuting Yan |
New compounds
| Abstracts Book Number | Category | Title | First author |
| 808 | New compounds | Phase 1b/2 study of maplirpacept (PF-07901801), tafasitamab, and lenalidomide in transplant-ineligible relapsed/refractory diffuse large B cell lymphoma participants | Adam J Olszewski |
| 809 | New compounds | Efficacy and Safety of Zanubrutinib Combined with R-CHOP in Newly Diagnosed Double Expressor Lymphoma: A Prospective Single-Arm Study | Jun Fang |
| 810 | New compounds | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma: Analysis of the Phase Ib Part | Liang Wang |
| 811 | New compounds | Rapid step-up dosing schedule of glofitamab is safe and efficacious in patients with relapsed/refractory diffuse large B cell lymphoma | Liang Wang |
| 812 | New compounds | Canadian Cancer Trials Group LY.18: A phase I master protocol of novel combination therapy for patients with relapsed/refractory lymphoma – the R-GDP-glofitamab substudy | Diego Villa |
| 813 | New compounds | Phase II Investigator-Initiated Trial of Epcoritamab-Lenalidomide in Treatment Naïve Follicular Lymphoma | Swetha Thiruvengadam |
| 814 | New compounds | First-line Selinexor in Combination with R-CHOP for EBV-Positive Diffuse Large B-Cell Lymphoma (Xplore): a single-arm, phase Ib/II trial | Qingqing Cai |
| 815 | New compounds | Glofitamab monotherapy in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): final analysis of a Phase I trial | Yu-Qin Song |
| 816 | New compounds | First Data Disclosure from Phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese Patients (Pts) With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Weili Zhao |
| 817 | New compounds | AdvanTIG-101: A Phase 1b/2 Study of Ociperlimab (anti-TIGIT) Plus Tislelizumab (anti-PD-1) or Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Yuqin Song |
| 818 | New compounds | Interim Analysis of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (PR-ICE) in Relapsed/Refractory DLBCL: A Phase I/II Study (PRIDE Study) | Weili Zhao |
| 819 | New compounds | A Phase I study of an Oral EZH2 Inhibitor TR115 in Patients with Relapsed or Refractory Non-Hodgkin's Lymphomas | Jie Jin |
| 820 | New compounds | Phase 2 Study of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, as Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: TAI-SHAN9 Trial | Lugui Qiu |
| 821 | New compounds | Open-label, phase 1 study of CD30-directed antibody drug conjugate, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: safety and preliminary efficacy | Swetha K. Thiruvengadam |
Ongoing trials
| Abstracts Book Number | Category | Title | First author |
| 822 | Ongoing trials | A Dose-Escalation Study of Intravenous Vesicular Stomatitis Virus to Treat Companion Dogs with Spontaneous Aggressive Lymphoma (Phase 1 of the ORBIT Clinical Trial) | Caitlin Michelle Feiock |
| 823 | Ongoing trials | A PHASE IA/IB OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC OF UBX-303061 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES | Wonseog Kim |
| 824 | Ongoing trials | R-CHOP with Sintilizumab in First-Line Treatment of Large B-Cell Lymphoma Patients with TP53 Mutations and PD-L1 expression: A Randomized, Multicenter Clinical Study | Yuxuan Che |
| 825 | Ongoing trials | Measuring symptom improvement in idiopathic multicentric Castleman disease: Emerging results from an inclusive, iterative process | Francis Shupo |
| 826 | Ongoing trials | PET-CT–Adapted Treatment for Early-Stage Diffuse Large B-Cell Lymphoma Without Risk Factors: Preliminary Analysis from the GATLA Group | Astrid Pavlovsky |
| 827 | Ongoing trials | Surzetoclax ABBV-453: Phase 1 Dose Escalation Study of Next-Generation BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Tanya Siddiqi |
| 828 | Ongoing trials | Trial in Progress: Pembrolizumab in Combination with Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (Pembro-CORE) | Hishan Tharmaseelan |
| 829 | Ongoing trials | Phase Ib Clinical Trial of Loncastuximab Tesirine and Roflumilast in Added to R-CHOP (Lo-RR-CHOP) for Treatment Naive High Risk Diffuse Large B Cell Lymphoma (DLBCL) | Adolfo Enrique Diaz Duque |
| 830 | Ongoing trials | A phase 1 study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting ADC in patients with relapsed/refractory B-cell non-Hodgkin lymphoma | Dai Maruyama |
| 831 | Ongoing trials | A Phase 1, Multicenter, First-in-Human Trial of GCC2005, an Allogeneic CAR-NK Cell Therapy Targeting CD5, in Patients with Relapsed/Refractory NK and T-Cell Malignancies | Won Seog Kim |
| 832 | Ongoing trials | A Phase II Trial of Orelabrutinib Combined with Zuberitamab in Previously Untreated Marginal Zone Lymphoma: A Multicenter, Single-Arm Study (ZOOM Trial) | Zhiming Li |
| 833 | Ongoing trials | PRO-MIND: Prospective Real-World Study of Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma in Italy – An Ongoing Trial | Pier Luigi Zinzani |
| 834 | Ongoing trials | Lifestyles implemented-Survivorship Care Plan (SCP) in lymphoma survivors: an ongoing randomized clinical trial by the Fondazione Italiana Linfomi (FIL) | Carla Minoia |
| 835 | Ongoing trials | A Multicenter, Open-Label, Ph 1 Study to Assess the Safety of P-CD19CD20-ALLO1, an Allogeneic CAR-T Cell Therapy, in Subjects with Relapsed/Refractory B Cell Malignancies | Taha Al-Juhaishi |
| 836 | Ongoing trials | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic countries (MERLIN) | Marianne Brodtkorb |
| 837 | Ongoing trials | Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma | Imke E. Karsten |
| 838 | Ongoing trials | A Phase 1 trial of NX-2127, a first-in-class BTK dual-targeted protein degrader, in patients with relapsed/refractory B-cell malignancies | Alexey Danilov |
| 839 | Ongoing trials | An ongoing Phase Ib trial assessing mosunetuzumab monotherapy and combined mosunetuzumab and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia | Paula Marlton |
| 840 | Ongoing trials | CLL-RT1 extension trial: Zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD1 inhibitor, plus sonrotoclax, a BCL2 inhibitor, for treatment of Richter Transformation | Othman Al-Sawaf |
| 841 | Ongoing trials | LATE-R trial: A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axi-cel in Patients with Late Relapse of Large B-Cell Lymphomas | Mariana Bastos-Oreiro |
| 842 | Ongoing trials | MyHodgkin MyHealth (MHMH) Survivorship App recruitment suggests high acceptability of patient-derived data in Hodgkin Lymphoma (HL) | Nicole Wong Doo |
| 843 | Ongoing trials | Ongoing Trial: A Phase I/II Study of Tafasitamab plus Lenalidomide in Patients with Relapsed Central Nervous System Lymphoma | James Louis Rubenstein |
| 844 | Ongoing trials | PRIMAVERA: A Phase I/II Study to Evaluate Safety and Efficacy of the PRMT5 Inhibitor AZD3470 in Participants with Relapsed/Refractory Hematologic Malignancies | Enrico Derenzini |
| 845 | Ongoing trials | Epcoritamab with R-miniCVP for Older Unfit/Frail or Anthracycline-Ineligible Adult Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase 2 Trial | Rahul Shah |
| 846 | Ongoing trials | Orelabrutinib plus bendamustine-rituximab (OBR) versus bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk mantle cell lymphoma (MCL) | Li Wang |
| 847 | Ongoing trials | PALT trial : First in class glyco‑humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL). | Gandhi Damaj |
| 848 | Ongoing trials | A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia | Zachary Erin Hunzeker |
| 849 | Ongoing trials | Interim PET-Adapted De-escalation Chemotherapy Regimen for Advanced Stage cHL Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine | Hun Ju Lee |
| 850 | Ongoing trials | GOLSEEK-2: A Phase 2 Randomized, Open-Label Study of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced-Stage Follicular Lymphoma | Pier Luigi Zinzani |
| 851 | Ongoing trials | TITANium: A multicenter Phase 1/2 study of AZD5492, a first-in-class CD8-guided trispecific T-cell engager, in patients with relapsed/refractory B-cell malignancies | Philip Thompson |
| 852 | Ongoing trials | GUIDANCE 05: A Prospective Randomized Study on Genotype-Guided Targeted Agents with POLA-RCHP（POLA-RCHP-X） vs. POLA-RCHP in Untreated Diffuse Large B-Cell Lymphoma | Peng-Peng Xu |
| 853 | Ongoing trials | CTEP Trial 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab | Raphael Steiner |
| 854 | Ongoing trials | Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA | Hua-Jay J Cherng |
| 855 | Ongoing trials | A Phase 3 Randomized Trial: Duvelisib vs Investigator Choice (Gemcitabine or Bendamustine) in Relapsed/Refractory Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype | Kate Cwynarski |
| 856 | Ongoing trials | MARSUN, a Phase III, Multicenter, Open Label, Randomized Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in R/R marginal zone lymphomas. | Sylvain Carras |
| 857 | Ongoing trials | A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen in frontline PTCL (Crescendo Trial) | Yun Kyoung Tiger |
| 858 | Ongoing trials | Optimizing Frontline Therapy for Diffuse Large B Cell Lymphoma (DLBCL) in Older Adults: A GLOfitamab-Based, Response-Adapted, Window-StYle Study (GLORY) | Pallawi Torka |
Radiation Therapy
| Abstracts Book Number | Category | Title | First author |
| 859 | Radiation Therapy | Novel Application of Deep-Learning Based MRI for Detection, Segmentation, and Radiotherapy Response Assessment in Primary and Secondary Central Nervous System Lymphoma | Brianna Hostler |
| 860 | Radiation Therapy | Low dose radiotherapy in the real world: A single centre United Kingdom (UK) 5 year retrospective review of low dose radiotherapy for low grade lymphoma | Ashley Poon-King |
| 861 | Radiation Therapy | Bridging Radiation Therapy in CAR-T therapy | Tianpei Li |
| 862 | Radiation Therapy | Radiotherapy as a CAR-T bridging strategy for patients with large B-cell lymphoma: A South Wales experience. | Gwenllian Edwards |
| 863 | Radiation Therapy | Radiotherapy in Pregnant Patients with Hodgkin`s Lymphoma: Clinical Outcomes and Dosimetric Assessment | Elżbieta Wojciechowska-Lampka |
| 864 | Radiation Therapy | Radiation Therapy in Early-Stage Classical Hodgkin Lymphoma (cHL): Weighing the Evidence from Realworld Data | Reyad Dada |
| 865 | Radiation Therapy | The Impact of Radiotherapy on Survival in Younger Patients with Advanced Aggressive B-Cell Lymphoma in the Rituximab Era: A Multi-Center Retrospective Analysis | Liang Wang |
Miscellanea
| Abstracts Book Number | Category | Title | First author |
| 866 | Miscellanea | Counseling/Rehabilitation of lymphoma sufferers in Asian set up | S Pal |
| 867 | Miscellanea | A Novel Treatment Regimen for Newly Diagnosed CAEBV Inducing a High Response Rate: PD-1 Inhibitor, L-Aspargase and Chidamide | Yi-ao Di |
| 868 | Miscellanea | Fertility-Focused Findings from the INSIGHTFUL Study: Clinicians’ Reflections on Counselling, Support, and Follow-Up Care Provided Throughout Oncologic Intervention | Alexa Molinari |
| 869 | Miscellanea | How to Implement the Administration of Bispecific Antibody Therapy into Community Practice | Tara M Graff |
| 870 | Miscellanea | Time to Access Care: Inequities in the Non-Hodgkin Lymphoma Patient Journey Across Brazilian Public and Private Healthcare Systems | Ruddy Dalfeor |
| 871 | Miscellanea | Surgery is highly effective for asymptomatic multicentric Castleman disease | Yukai Duan |
| 872 | Miscellanea | Lymphadenopathy in Systemic Lupus Erythematosus: Characteristics and Development of a Predictive Risk Model. | Blanca Sanchez-Gonzalez |
| 873 | Miscellanea | Disparities in Lymphoma Treatment Access at Riau, one of Province in Indonesia : When Late Diagnosis and Unequal Care Define Outcomes | Nanda Noor Muhammad Nasution |
| 874 | Miscellanea | Time toxicity in the era of bispecific antibody treatment in relapsed/refractory non-Hodgkin lymphoma: concept elicitation with hematologists and patient perspectives | Ajay Major |
| 875 | Miscellanea | Joint analysis of 1695 cases of Malignant Lymphoma from the Ukranian and Cluj Napoca Lymphoma registries | Nazarii Shokun |
| 876 | Miscellanea | Lymphoma-associated bone marrow hemophagocytosis(LA-BMHPC):A retrospective,single-center study of 67 patients | Feiyang Zong |
| 877 | Miscellanea | Spanish idiopathic Multicentric Castleman Disease (iMCD) Registry. Epidemiology of iMCD in Spain (ARCANA) - Prevalence Cohort | José Tomás Navarro Ferrando |
| 878 | Miscellanea | DDeveloping an Outpatient Bispecific Antibody Therapy Program: Infrastructure and Tools from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Nazila Shafagati |
| 879 | Miscellanea | Geographic Treatment Patterns and Survival Outcomes in US Veterans Aged ≥80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma | Lindsey Fitzgerald |
| 880 | Miscellanea | Evaluating Patient Navigation Programs in Reducing Cancer Disparities in an Archipelagic Region: Lessons from Awal Bros Hospital, Riau, Indonesia | Nanda Noor Muhammad Nasution |
| 881 | Miscellanea | Epidemiology, treatment pattern and survival of human immunodeficiency virus infection-associated lymphoma in China | Chaoyu Wang |
| 882 | Miscellanea | Characteristics of Second Primary Malignancies Following Bispecific Antibodies Therapy | Liang Wang |
| 883 | Miscellanea | Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience from Romania and Greece | Ciprian Tomuleasa |
| 884 | Miscellanea | The Emotional Burden of Lymphoma: How Lymphoma Survivors Perceive Relationships and Self-Image | Nazarii Shokun |
| 885 | Miscellanea | Global burden of Hodgkin and non-Hodgkin lymphoma: current trends and projected incidence and mortality rates by 2050 | Yue Chai |
| 886 | Miscellanea | Return to norm after lymphoma chemotherapy: social, psychological and biological determinants of altered quality of life | Lucie Obéric |
| 887 | Miscellanea | Cytokine Storm Warning: Differentiating Lymphoma-Associated HLH from Lymphoid Malignancy Through Inflammatory Profiling | Swaminathan P Iyer |
| 888 | Miscellanea | Healthcare Resource Utilization and Costs in the Management of Patients with idiopathic Multicentric Castleman Disease in the United States | Ariela Noy |
| 889 | Miscellanea | Worldwide Experience of Chronic Active Epstein-Barr Virus Infection: A Multinational Retrospective Cohort Study | Xinran Wang |
| 890 | Miscellanea | Dynamic Varying in Secondary Primary Malignancies in DLBCL Survivors: A Comparative Study of the Pre- and Post-Rituximab Eras | Liang Wang |
| 891 | Miscellanea | Investigating Global Gender Demographics and Equity Among Hematologists | Carla Casulo |
| 892 | Miscellanea | The use of peripheral intravenous catheters (PIV) for lymphoma patients receiving anthracycline-based chemotherapy: a multicenter real-world analysis (RWA) | Yun Kyoung Tiger |
| 893 | Miscellanea | The Safety and Feasibility of Intravenous Vesicular Stomatitis Virus, an Immunogenic Oncolytic Virus, as a Treatment for Spontaneous Aggressive Lymphoma in Companion Dogs | Kelly M Reid |
| 894 | Miscellanea | Real life experience with siltuximab in Castleman disease | Ciprian Tomuleasa |